Guggenheim Initiates CG Oncology (CGON) Coverage with $90 PT, Highlights Bladder Cancer Therapeutic Cretostimogene

CG Oncology Inc. (NASDAQ:CGON) is one of the best hot stocks to invest in. On October 8, Guggenheim analyst Brad Canino initiated coverage of CG Oncology with a Buy rating and $90 price target. The firm believes that the non-muscle invasive bladder cancer market has lots of patients and pricing power. Guggenheim also highlighted CG Oncology’s cretostimogene, which will enter FDA review in 2026.

It was in its Q2 2025 earnings update that the company reported that it is developing cretostimogene grenadenorepvec, which is an investigational oncolytic immunotherapy, as a potential bladder-sparing therapeutic for NMIBC.

CG Oncology also initiated the CORE-008 Cohort CX trial, which is evaluating the combination of cretostimogene and gemcitabine in high-risk NMIBC patients. Upcoming milestones include the completion of Phase 3 enrollment for the PIVOT-006 trial in Q3 and the initiation of a BLA submission for cretostimogene in Q4.

CG Oncology Inc. (NASDAQ:CGON) is a late-stage clinical biopharmaceutical company that develops and commercializes backbone bladder-sparing therapeutics for patients with bladder cancer.

While we acknowledge the potential of CGON as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.